Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
303 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Osteoporosis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Osteoporosis - Pipeline Review, H2 2015', provides an overview of the Osteoporosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoporosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoporosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteoporosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Osteoporosis Overview 12 Therapeutics Development 13 Pipeline Products for Osteoporosis - Overview 13 Pipeline Products for Osteoporosis - Comparative Analysis 14 Osteoporosis - Therapeutics under Development by Companies 15 Osteoporosis - Therapeutics under Investigation by Universities/Institutes 22 Osteoporosis - Pipeline Products Glance 23 Late Stage Products 23 Clinical Stage Products 24 Early Stage Products 25 Unknown Stage Products 26 Osteoporosis - Products under Development by Companies 27 Osteoporosis - Products under Investigation by Universities/Institutes 34 Osteoporosis - Companies Involved in Therapeutics Development 35 Alethia Biotherapeutics Inc. 35 Alize Pharma SAS 36 Alkem Laboratories Ltd. 37 Amgen Inc. 38 Amura Holdings Limited 39 Arcarios BV 40 Astellas Pharma Inc. 41 Bone Medical Limited 42 Bone Therapeutics SA 43 Caladrius Biosciences, Inc. 44 Chronos Therapeutics Limited 45 Chugai Pharmaceutical Co., Ltd. 46 Corium International, Inc. 47 Critical Pharmaceuticals Limited 48 Daiichi Sankyo Company, Limited 49 ElexoPharm GmbH 50 Eli Lilly and Company 51 EndoCeutics, Inc. 52 Enzo Biochem, Inc. 53 F. Hoffmann-La Roche Ltd. 54 Galapagos NV 55 Glide Pharmaceutical Technologies Limited 56 Hanmi Pharmaceuticals, Co. Ltd. 57 Haoma Medica Ltd. 58 IMMD Inc. 59 Immunovo BV 60 Inbiopro Solutions Pvt. Ltd. 61 Kaken Pharmaceutical Co., Ltd. 62 Kolltan Pharmaceuticals, Inc. 63 Korea Kolmar Co. Ltd. 64 Lead Discovery Center GmbH 65 Ligand Pharmaceuticals, Inc. 66 Lotus Pharmaceutical Co., Ltd. 67 Lupin Limited 68 Medivir AB 69 Merck & Co., Inc. 70 Mereo Biopharma Group Limited 71 Merrion Pharmaceuticals Plc 72 Novartis AG 73 Omeros Corporation 74 Oncobiologics, Inc. 75 Oscotec Inc. 76 Osteologix Holdings Plc 77 Pantarhei Bioscience BV 78 Paras Biopharmaceuticals Finland Oy 79 Pfizer Inc. 80 PhytoHealth Corporation 81 PolyNovo Limited 82 R-Pharm 83 Radius Health, Inc. 84 Richter-Helm BioTec GmbH & Co. KG 85 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 86 Shin Poong Pharm.Co., Ltd. 87 Sinil Pharmaceutical Co., Ltd 88 STELIS Biopharma Pvt. Ltd. 89 Sumitomo Dainippon Pharma Co., Ltd. 90 Takeda Pharmaceutical Company Limited 91 TAmiRNA GmbH 92 TechnoPhage SA 93 Uni-Bio Science Group Ltd. 94 Unigene Laboratories, Inc. (Inactive) 95 Wroclawskie Centrum Badan EIT+ Sp. z o.o. 96 Zosano Pharma Corporation 97 Zydus Cadila Healthcare Limited 98 Osteoporosis - Therapeutics Assessment 99 Assessment by Monotherapy Products 99 Assessment by Combination Products 100 Assessment by Target 101 Assessment by Mechanism of Action 104 Assessment by Route of Administration 107 Assessment by Molecule Type 109 Drug Profiles 111 (aceclofenac + eperisone) - Drug Profile 111 (prasterone + acolbifene hydrochloride) - Drug Profile 112 2-AMD - Drug Profile 113 AB-25E9 - Drug Profile 114 abaloparatide - Drug Profile 115 alendronate sodium - Drug Profile 118 alendronate sodium - Drug Profile 120 AM-3701 - Drug Profile 121 AOD-9604 - Drug Profile 122 ARC-205 - Drug Profile 124 AS-2690168 - Drug Profile 125 astrogorgiadiol - Drug Profile 126 bazedoxifene acetate - Drug Profile 127 Biosimilar for Osteoporosis - Drug Profile 128 blosozumab - Drug Profile 129 BMD-1111 - Drug Profile 130 BN-005 - Drug Profile 132 BN-008 - Drug Profile 133 BPS-804 - Drug Profile 134 calcitonin - Drug Profile 136 CDR-914K058 - Drug Profile 138 CDRI-99/373 - Drug Profile 139 CH-5036249 - Drug Profile 141 denosumab - Drug Profile 142 denosumab biosimilar - Drug Profile 145 denosumab biosimilar - Drug Profile 146 DPF-020 - Drug Profile 147 Drug to Inhibit miR-31 for Osteoporosis - Drug Profile 148 Drug to Target miR-002 for Osteoporosis - Drug Profile 149 Drugs for Postmenopausal Osteoporosis - Drug Profile 150 Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 151 DS-1501 - Drug Profile 152 estetrol - Drug Profile 153 Eu-232 - Drug Profile 155 genipin - Drug Profile 156 ibandronate sodium - Drug Profile 157 IBPB-008IG - Drug Profile 159 IHBD-1 - Drug Profile 160 IMD-2560 - Drug Profile 161 K-671 - Drug Profile 162 KKM-0805 - Drug Profile 163 KKM-0902 - Drug Profile 164 lasofoxifene tartrate - Drug Profile 165 MAb-7 - Drug Profile 167 MIV-711 - Drug Profile 168 Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis - Drug Profile 169 Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis - Drug Profile 170 MOR-106 - Drug Profile 171 NBS-101 - Drug Profile 172 NEP-28 - Drug Profile 174 OCT-1547 - Drug Profile 175 odanacatib - Drug Profile 176 ODS-656 - Drug Profile 178 Oratonin - Drug Profile 179 OXY-149 - Drug Profile 180 PHN-031 - Drug Profile 182 poncirin - Drug Profile 183 PREOB - Drug Profile 184 Proteins to Inhibit RANKL for Oncology and Osteoporosis - Drug Profile 185 RDC-5 - Drug Profile 186 Recombinant Protein 1 for Rheumatoid Arthritis and Osteoporosis - Drug Profile 188 Recombinant Protein 2 for Rheumatoid Arthritis and Osteoporosis - Drug Profile 189 Recombinant Protein 3 for Rheumatoid Arthritis and Osteoporosis - Drug Profile 190 Recombinant Protein for Osteoporosis - Drug Profile 191 Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis - Drug Profile 192 Recombinant Protein to Inhibit Serine Protease for Bone Disorders and Osteoporosis - Drug Profile 193 risedronate sodium - Drug Profile 194 romosozumab - Drug Profile 195 RPH-203 - Drug Profile 197 S-007-1500 - Drug Profile 198 S-101479 - Drug Profile 199 S-49288 - Drug Profile 200 SBL-001 - Drug Profile 201 SI-000513 - Drug Profile 202 Small Molecule to Agonize LRP for Osteoporosis - Drug Profile 203 Small Molecule to Agonize PTH-1R for Osteoporosis - Drug Profile 204 Small Molecule to Inhibit Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis - Drug Profile 205 Small Molecule to Modulate Estrogen Receptor for Breast Cancer and Osteoporosis - Drug Profile 206 Small Molecule to Target LGR4 for Cancer and Osteoporosis - Drug Profile 207 Small Molecule to Target OGR1 for Oncology, Bone Diseases, Asthma and Osteoporosis - Drug Profile 208 Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 209 Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile 210 Small Molecules for Osteopenia and Osteoporosis - Drug Profile 211 Small Molecules for Osteoporosis - Drug Profile 212 Small Molecules for Osteoporosis - Drug Profile 213 Small Molecules for Osteoporosis - Drug Profile 214 Small Molecules for Primary Juvenile Osteoporosis - Drug Profile 216 Small Molecules to Activate CB2 for Osteoporosis - Drug Profile 217 Small Molecules to Agonize Androgen Receptor for Osteoporosis - Drug Profile 218 Small Molecules to Agonize Glucocorticoid Receptor for Osteoporosis - Drug Profile 219 Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis - Drug Profile 220 Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis - Drug Profile 221 Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 222 Small Molecules to Inhibit Src Tyrosine Kinase for Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 223 Sodium Quinate - Drug Profile 224 SP-35454 - Drug Profile 225 SR-2595 - Drug Profile 226 Stem Cell Therapy for Osteoporosis and Periodontitis - Drug Profile 227 Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile 228 Synthetic Peptide for Osteoporosis and Osteoarthritis - Drug Profile 229 TAK-075 - Drug Profile 230 teriparatide - Drug Profile 231 teriparatide - Drug Profile 233 teriparatide - Drug Profile 234 teriparatide - Drug Profile 235 teriparatide - Drug Profile 236 teriparatide acetate - Drug Profile 237 teriparatide biosimilar - Drug Profile 239 teriparatide biosimilar - Drug Profile 240 TZ-121 - Drug Profile 241 Vaccine to Target Sclerostin for Osteoporosis - Drug Profile 242 VS-105 - Drug Profile 243 VS-401 - Drug Profile 244 VS-411 - Drug Profile 245 zoledronic acid - Drug Profile 246 Osteoporosis - Recent Pipeline Updates 248 Osteoporosis - Dormant Projects 273 Osteoporosis - Discontinued Products 282 Osteoporosis - Product Development Milestones 284 Featured News & Press Releases 284 Appendix 294 Methodology 294 Coverage 294 Secondary Research 294 Primary Research 294 Expert Panel Validation 294 Contact Us 294 Disclaimer 295
List of Tables
Number of Products under Development for Osteoporosis, H2 2015 21 Number of Products under Development for Osteoporosis - Comparative Analysis, H2 2015 22 Number of Products under Development by Companies, H2 2015 24 Number of Products under Development by Companies, H2 2015 (Contd..1) 25 Number of Products under Development by Companies, H2 2015 (Contd..2) 26 Number of Products under Development by Companies, H2 2015 (Contd..3) 27 Number of Products under Development by Companies, H2 2015 (Contd..4) 28 Number of Products under Development by Companies, H2 2015 (Contd..5) 29 Number of Products under Investigation by Universities/Institutes, H2 2015 30 Comparative Analysis by Late Stage Development, H2 2015 31 Comparative Analysis by Clinical Stage Development, H2 2015 32 Comparative Analysis by Early Stage Development, H2 2015 33 Comparative Analysis by Unknown Stage Development, H2 2015 34 Products under Development by Companies, H2 2015 35 Products under Development by Companies, H2 2015 (Contd..1) 36 Products under Development by Companies, H2 2015 (Contd..2) 37 Products under Development by Companies, H2 2015 (Contd..3) 38 Products under Development by Companies, H2 2015 (Contd..4) 39 Products under Development by Companies, H2 2015 (Contd..5) 40 Products under Development by Companies, H2 2015 (Contd..6) 41 Products under Investigation by Universities/Institutes, H2 2015 42 Osteoporosis - Pipeline by Alethia Biotherapeutics Inc., H2 2015 43 Osteoporosis - Pipeline by Alize Pharma SAS, H2 2015 44 Osteoporosis - Pipeline by Alkem Laboratories Ltd., H2 2015 45 Osteoporosis - Pipeline by Amgen Inc., H2 2015 46 Osteoporosis - Pipeline by Amura Holdings Limited, H2 2015 47 Osteoporosis - Pipeline by Arcarios BV, H2 2015 48 Osteoporosis - Pipeline by Astellas Pharma Inc., H2 2015 49 Osteoporosis - Pipeline by Bone Medical Limited, H2 2015 50 Osteoporosis - Pipeline by Bone Therapeutics SA, H2 2015 51 Osteoporosis - Pipeline by Caladrius Biosciences, Inc. , H2 2015 52 Osteoporosis - Pipeline by Chronos Therapeutics Limited, H2 2015 53 Osteoporosis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2015 54 Osteoporosis - Pipeline by Corium International, Inc., H2 2015 55 Osteoporosis - Pipeline by Critical Pharmaceuticals Limited, H2 2015 56 Osteoporosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 57 Osteoporosis - Pipeline by ElexoPharm GmbH, H2 2015 58 Osteoporosis - Pipeline by Eli Lilly and Company, H2 2015 59 Osteoporosis - Pipeline by EndoCeutics, Inc., H2 2015 60 Osteoporosis - Pipeline by Enzo Biochem, Inc., H2 2015 61 Osteoporosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 62 Osteoporosis - Pipeline by Galapagos NV, H2 2015 63 Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2015 64 Osteoporosis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015 65 Osteoporosis - Pipeline by Haoma Medica Ltd., H2 2015 66 Osteoporosis - Pipeline by IMMD Inc., H2 2015 67 Osteoporosis - Pipeline by Immunovo BV, H2 2015 68 Osteoporosis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015 69 Osteoporosis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2015 70 Osteoporosis - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2015 71 Osteoporosis - Pipeline by Korea Kolmar Co. Ltd., H2 2015 72 Osteoporosis - Pipeline by Lead Discovery Center GmbH, H2 2015 73 Osteoporosis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 74 Osteoporosis - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2015 75 Osteoporosis - Pipeline by Lupin Limited, H2 2015 76 Osteoporosis - Pipeline by Medivir AB, H2 2015 77 Osteoporosis - Pipeline by Merck & Co., Inc., H2 2015 78 Osteoporosis - Pipeline by Mereo Biopharma Group Limited, H2 2015 79 Osteoporosis - Pipeline by Merrion Pharmaceuticals Plc, H2 2015 80 Osteoporosis - Pipeline by Novartis AG, H2 2015 81 Osteoporosis - Pipeline by Omeros Corporation, H2 2015 82 Osteoporosis - Pipeline by Oncobiologics, Inc., H2 2015 83 Osteoporosis - Pipeline by Oscotec Inc., H2 2015 84 Osteoporosis - Pipeline by Osteologix Holdings Plc, H2 2015 85 Osteoporosis - Pipeline by Pantarhei Bioscience BV, H2 2015 86 Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2015 87 Osteoporosis - Pipeline by Pfizer Inc., H2 2015 88 Osteoporosis - Pipeline by PhytoHealth Corporation, H2 2015 89 Osteoporosis - Pipeline by PolyNovo Limited, H2 2015 90 Osteoporosis - Pipeline by R-Pharm, H2 2015 91 Osteoporosis - Pipeline by Radius Health, Inc., H2 2015 92 Osteoporosis - Pipeline by Richter-Helm BioTec GmbH & Co. KG, H2 2015 93 Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015 94 Osteoporosis - Pipeline by Shin Poong Pharm.Co., Ltd., H2 2015 95 Osteoporosis - Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2015 96 Osteoporosis - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2015 97 Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 98 Osteoporosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 99 Osteoporosis - Pipeline by TAmiRNA GmbH, H2 2015 100 Osteoporosis - Pipeline by TechnoPhage SA, H2 2015 101 Osteoporosis - Pipeline by Uni-Bio Science Group Ltd., H2 2015 102 Osteoporosis - Pipeline by Unigene Laboratories, Inc. (Inactive), H2 2015 103 Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H2 2015 104 Osteoporosis - Pipeline by Zosano Pharma Corporation, H2 2015 105 Osteoporosis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 106 Assessment by Monotherapy Products, H2 2015 107 Assessment by Combination Products, H2 2015 108 Number of Products by Stage and Target, H2 2015 110 Number of Products by Stage and Mechanism of Action, H2 2015 113 Number of Products by Stage and Route of Administration, H2 2015 116 Number of Products by Stage and Molecule Type, H2 2015 118 Osteoporosis Therapeutics - Recent Pipeline Updates, H2 2015 256 Osteoporosis - Dormant Projects, H2 2015 281 Osteoporosis - Dormant Projects (Contd..1), H2 2015 282 Osteoporosis - Dormant Projects (Contd..2), H2 2015 283 Osteoporosis - Dormant Projects (Contd..3), H2 2015 284 Osteoporosis - Dormant Projects (Contd..4), H2 2015 285 Osteoporosis - Dormant Projects (Contd..5), H2 2015 286 Osteoporosis - Dormant Projects (Contd..6), H2 2015 287 Osteoporosis - Dormant Projects (Contd..7), H2 2015 288 Osteoporosis - Dormant Projects (Contd..8), H2 2015 289 Osteoporosis - Discontinued Products, H2 2015 290 Osteoporosis - Discontinued Products (Contd..1), H2 2015 291
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
